NCT00678119已完成2 期
A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib
Argos Therapeutics14 个研究点 分布在 2 个国家目标入组 25 人开始时间: 2008年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
- 试验地点
- 14
- 主要终点
- Clinical antitumor activity will be assessed as an objective tumor response as defined by RECIST. Tumor response is documented using standard definitions of CR and must be confirmed no less than 4 weeks after the criteria for response are first met.
研究概览
简要总结
Study to investigate an anticancer cellular immunotherapeutic, AGS-003, when used in combination with sunitinib in subjects with previously untreated advanced stage RCC.
详细描述
The purpose of this study is to investigate an anticancer immunotherapeutic, AGS-003, when used in combination with sunitinib (the treatment regimen) in a single-stage, Phase II design in subjects with previously untreated advanced stage RCC after nephrectomy/excisional biopsy/metastasectomy. AGS-003 is formulated using mature DCs co-electroporated with CD40L IVT RNA and autologous total tumor RNA
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects ≥18 years of age with newly diagnosed advanced stage RCC will be eligible for inclusion in this study if all of the following criteria apply:
- •Newly diagnosed advanced stage RCC.
- •Eligible for unilateral nephrectomy or partial nephrectomy; OR, Has lesion accessible for excisional biopsy/metastasectomy.
- •Measurable disease.
- •Candidate for sunitinib treatment as labeled.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Memorial Sloan Kettering Cancer Center (MSKCC) risk group 0 or
- •No brain metastases detected by MRI.
- •Normal renal function in the contralateral kidney.
- •Able to abstain from taking prohibited prescription or prohibited non-prescription drugs.
- •Use of appropriate birth control methods for the duration of the study for women of childbearing potential and men with female partners of childbearing potential.
- •Clinically acceptable Screening results according to the following specific limits:
- •Adequate hematologic function.
- •Adequate renal and hepatic function.
- •Adequate coagulation function.
- •Normal serum calcium.
- •Ability to communicate effectively with study personnel; considered reliable, willing, and cooperative in terms of compliance with the Protocol requirements.
- •Voluntary informed consent given to participate in the study.
排除标准
- •Subjects will NOT be eligible for inclusion in this study if any of the following criteria apply:
- •Nephrectomy for RCC therapy is required.
- •Any serious medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational treatment.
- •Uncontrolled hypertension.
- •Type I diabetes mellitus (insulin therapy for Type II diabetes IS permitted).
- •Prior systemic therapy for advanced stage RCC.
- •Active autoimmune disease.
- •Prior history of malignancy other than RCC within the preceding 5 years, except for adequately treated cervical cancer or non-melanoma skin cancer.
- •Use of prohibited prescription or prohibited non-prescription drugs during 2 months prior to entry into the study.
- •Active, acute, or chronic clinically significant infections.
- •Use of another investigational drug or participation in any investigational drug study within the 28 days prior to the start of study enrollment.
- •Planned or elective anti-cancer surgical treatment other than nephrectomy/excisional biopsy/metastasectomy.
- •History of hypercalcemia, symptomatic hypercalcemia, or hypercalcemia requiring management.
- •Known hypersensitivity to dimethyl sulfoxide (DMSO).
- •Body weight less than 30 kg.
- •Pregnancy or lactation.
研究组 & 干预措施
1: AGS-003+sunitinib
Experimental
Single arm study AGS-003 plus sunitinib
干预措施: AGS-003 (Biological)
1: AGS-003+sunitinib
Experimental
Single arm study AGS-003 plus sunitinib
干预措施: Sunitinib (Drug)
结局指标
主要结局
Clinical antitumor activity will be assessed as an objective tumor response as defined by RECIST. Tumor response is documented using standard definitions of CR and must be confirmed no less than 4 weeks after the criteria for response are first met.
时间窗: 24 weeks
次要结局
- The monitoring of clinical activity, immune response and safety across multiple doses.(24 weeks)
研究者
研究点 (14)
Loading locations...
相似试验
终止
2 期
A Rollover Protocol for Subjects Previously Treated With AGS-003Renal Cell CarcinomaNCT01482949Argos Therapeutics2
招募中
2 期
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.Non-small Cell Lung CancerNCT05351788Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.110
已完成
2 期
Safety and Efficacy Study of AGS-004 During Analytical Treatment InterruptionHIV InfectionNCT01069809Argos Therapeutics53
已完成
2 期
Antithymocyte Globulin and Cyclosporine to Treat MyelodysplasiaMyelodysplastic SyndromeNCT00005937Neal Young, M.D.42
撤回
3 期
Evaluation of the Immunogenicity and Safety of Concomitant Administration of Novel Oral Polio Type 2 Vaccine and Bivalent Oral Polio VaccinePoliomyelitisNCT05166031Fidec Corporation